No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Nippon Shinyaku Co., Ltd., an enterprise established in Kyoto, Japan, in 1911, engages globally in the production and distribution of pharmaceutical products and functional foods. Its reach extends across Japan, Switzerland, and various international markets, with operations structured into two core divisions: Pharmaceuticals and Functional Food. The Pharmaceutical division concentrates on a wide array of therapeutic areas, encompassing conditions affecting the urinary system, inflammatory and allergic responses, hematologic malignancies, cardiovascular and metabolic disorders, gastrointestinal issues, and other diverse diseases. Its extensive product catalog features notable treatments such as Zalutia, designed for urinary difficulties arising from benign prostatic hypertrophy; Eviprostat, also for prostatic hypertrophy; Bladderon for frequent urination; and Estracyt, targeting prostate cancer. For erectile dysfunction, it provides Cialis. In hematology and oncology, the company's portfolio includes Vidaza for myelodysplastic syndrome; Cylocide and CylocideN for solid tumors, acute leukemia, and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku also offers Uptravi, Adcirca, and Opsumit for the management of pulmonary arterial hypertension, alongside VILTEPSO for muscular dystrophy. Other specialized medications include Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect, aimed at maintaining alcohol abstinence; and Onetram and Tramal for the treatment of cancer and chronic pain. Furthermore, the company actively conducts research, development, and marketing efforts in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment broadens the company's offerings, supplying various health-focused ingredients, food preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.
www.nippon-shinyaku.co.jpNo one on the platform currently holds 4516.T.
No tracked institution reports a position in 4516.T as of their last filing.
No one on the platform has traded 4516.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 12.4% | 14.4% | 14.5% | — | — | — |
| Rev. Growth % | 6.6% | 7.0% | ||||
| Profit Margin % | 17.4% | 17.8% | 15.9% | |||
| Free Cash Flow Margin % | 14.2% | 13.9% | 12.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $191.0B | +12.6% | $408.60 | $309.00–$500.60 | — | 8 |
| 2028 | $168.3B | -11.9% | $188.51 | $47.80–$376.83 | — | 8 |
| 2029 | $167.7B | -0.3% | $120.01 | $-27.98–$236.05 | — | 6 |
| 2030 | $163.1B | -2.8% | $48.71 | $43.56–$53.77 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $96.15 | $145.88 | +51.7% |
| 2026-05-15 | $69.25 | $57.50 | -17.0% |
| 2026-02-09 | $70.00 | $149.62 | +113.7% |
| 2025-11-14 | $83.60 | $111.36 | +33.2% |
| 2025-08-07 | $83.27 | $122.52 | +47.1% |
| 2025-05-08 | $33.74 | $59.47 | +76.3% |
| 2025-02-07 | $131.88 | $180.84 | +37.1% |
| 2024-11-13 | $92.62 |
| $90.69 |
| -2.1% |
| -0.58% |
| $280.8B |
| — |
| 4544.TH.U. Group Holdings, Inc. | $3488.00 | +0.55% | $193.5B | — |
| 4547.TKissei Pharmaceutical Co., Ltd. | $4020.00 | +0.00% | $166.6B | — |
Source: Financial Modeling Prep · peers by sector/industry